Pathology: Receptors and Subtypes

John introduces how ER/PR and HER2 status define luminal, HER2-enriched, and triple-negative breast cancer subtypes.

Play episode from 04:47

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!